Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Exicure, Inc. is a clinical-stage biotechnology company focused on developing nucleic acid-based therapeutics using its proprietary Spherical Nucleic Acid (SNA) technology platform. The company operates within the biotechnology and life sciences industries, with research emphasis on immunology, oncology, and genetic and inflammatory diseases. Its core value proposition centers on the unique structural and functional properties of SNAs, which are designed to enable targeted immune modulation and gene regulation.
The company’s primary historical revenue drivers have been research and development activities rather than commercialized products, as none of its therapeutic candidates have reached regulatory approval. Exicure was founded in 2011 as a spinout from academic research at Northwestern University, based on discoveries by its scientific founders. Over time, the company advanced multiple preclinical and early clinical programs but later narrowed its focus and reduced operations as part of strategic reviews and capital preservation efforts. Public disclosures indicate the company has explored strategic alternatives amid financial constraints.
Business Operations
Exicure’s operations have historically been organized around a single operating segment focused on the discovery and development of SNA-based therapeutics. The company generated no material product revenue and relied primarily on equity financing and limited collaboration-related income to fund operations. Its lead development efforts included immune-stimulatory SNAs designed to activate toll-like receptors and gene-regulating SNAs targeting specific disease pathways.
Operational activities have been primarily domestic, with research and corporate functions based in the United States. The company controls intellectual property licensed from Northwestern University related to SNA chemistry and therapeutic applications. As of the most recent public disclosures, Exicure significantly reduced its workforce and development activities, and some pipeline programs were paused or discontinued. Data inconclusive based on available public sources regarding any active joint ventures or revenue-generating partnerships currently in place.
Strategic Position & Investments
Strategically, Exicure positioned itself as a platform innovator rather than a single-asset biotechnology company, seeking to apply SNA technology across multiple disease areas. Growth initiatives historically included advancing lead candidates into clinical trials and pursuing partnerships with larger pharmaceutical companies. The company also invested heavily in intellectual property protection and translational research to differentiate SNAs from conventional nucleic acid therapies.
Major investments primarily consisted of internal R&D spending rather than acquisitions. The company did not report material subsidiary acquisitions or a diversified investment portfolio. In recent years, management disclosed efforts to evaluate strategic alternatives, which may include asset sales, licensing transactions, or corporate restructuring. Information on emerging technologies beyond the SNA platform is inconclusive based on available public sources.
Geographic Footprint
Exicure’s operational footprint has been concentrated in North America, with headquarters historically located in Illinois, United States. Research, development, and administrative activities have been primarily U.S.-based, with no indication of large-scale international manufacturing or commercial operations.
While the company’s intellectual property has potential global applicability, its direct market presence outside the United States has been limited. International influence has largely taken the form of global patent filings and scientific collaboration rather than physical operations or subsidiaries in Europe or Asia-Pacific. Data inconclusive based on available public sources regarding any current international offices or employees.
Leadership & Governance
Exicure was co-founded by academic scientists associated with the discovery of SNA technology, including Chad A. Mirkin, who played a foundational role in the underlying science. Over time, leadership transitioned toward executives with biotechnology development and public company experience. Governance has been overseen by a board of directors responsible for strategic direction, capital allocation, and oversight of restructuring activities.
Public filings confirm several key executives have served in senior roles, though recent leadership changes and interim appointments create some uncertainty regarding current positions. Data inconclusive based on available public sources regarding the permanent appointment of a current Chief Executive Officer.
- Chad A. Mirkin – Co-Founder and Scientific Founder
- David Giljohann – Former Chief Scientific Officer
- Robert Brown – Former Chief Executive Officer
- Michael Cavanaugh – Former Chief Financial Officer